U.S. Meniere's Disease Drug Market - Industry Trends and Forecast To 2027

1 INTRODUCTION 11

1.1 OBJECTIVES OF THE STUDY 11

1.2 MARKET DEFINITION 11

1.3 OVERVIEW OF U.S. MENIERE’S DISEASE DRUG MARKET 11

1.4 LIMITATIONS 12

1.5 MARKETS COVERED 13

2 MARKET SEGMENTATION 14

2.1 MARKETS COVERED 14

2.2 GEOGRAPHICAL SCOPE 15

2.3 YEARS CONSIDERED FOR THE STUDY 15

2.4 CURRENCY AND PRICING 15

2.5 DBMR TRIPOD DATA VALIDATION MODEL 16

2.6 MULTIVARIATE MODELLING 19

2.7 PRODUCTS LIFELINE CURVE 19

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 20

2.9 DBMR MARKET POSITION GRID 21

2.10 VENDOR SHARE ANALYSIS 22

2.11 SECONDARY SOURCES 23

2.12 ASSUMPTIONS 23

3 EXECUTIVE SUMMARY 24

4 PREMIUM INSIGHTS 26

5 EPIDEMIOLOGY 27

6 MARKET OVERVIEW 28

6.1 DRIVERS 30

6.1.1 INCREASING PREVALNCE OF MENIERE’S DISEASE 30

6.1.2 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT OF THE DISEASE 32

6.2 RESTRAINTS 33

6.2.1 UNMET MEDICAL NEEDS 33

6.2.2 RIGOROUS REGULATIONS PROTOCOLS 33

6.3 OPPORTUNITIES 34

6.3.1 INCREASING RESEARCH ACTIVITIES FOR MENIERE’S DISEASE 34

6.3.2 RISING GRANTS IN THE RESEARCH & DEVELOPMENT FOR DRUG DEVELOPMENT 34

6.3.3 LACK OF APPROVED DRUG 35

6.4 CHALLENGES 36

6.4.1 LOW INTEREST OF PHARMACEUTICAL COMPANIES TOWARDS ORPHAN DRUG DEVELOPMENT 36

6.4.2 AVAILABILITY OF ALTERNATIVE MEDICINES, DEVICES AND SURGERIES 36

6.4.3 CHALLENGING DIAGNOSIS AND TREATMENT 37

7 U.S. MENIERE’S DISEASE DRUG MARKET, BY TYPE 38

7.1 OVERVIEW 39

7.2 CLASSIC 42

7.3 BILATERAL 42

7.4 VESTIBULAR 42

8 U.S. MENIERE’S DISEASE DRUG MARKET, BY TREATMENT 43

8.1 OVERVIEW 44

8.2 OFF LABEL DRUGS 47

8.2.1 TRANQUILLIZERS 48

8.2.1.1 DIAZEPAM 48

8.2.1.2 LORAZEPAM 48

8.2.1.3 OTHERS 48

8.2.2 ANTIHISTAMINIC AGENTS 48

8.2.2.1 BETAHISTINE 49

8.2.2.2 PROMETHAZINE 49

8.2.2.3 DIMENHYDRINATE 49

8.2.2.4 MECLIZINE HYDROCHLORIDE 49

8.2.2.5 OTHERS 49

8.2.3 DIURETIC AGENTS 50

8.2.3.1 HYDROCHLOROTHIAZIDE 50

8.2.3.2 ACETAZOLAMIDE 50

8.2.3.3 TRIAMTERENE 50

8.2.3.4 OTHERS 50

8.2.4 ANTIBIOTIC AGENTS 51

8.2.4.1 GENTAMICIN 51

8.2.4.2 STREPTOMYCIN 51

8.2.4.3 OTHERS 51

8.2.5 CORTICOSTEROIDS 51

8.2.5.1 PREDNISONE 52

8.2.5.2 DEXAMETHASONE 52

8.2.5.3 OTHERS 52

8.2.6 OTHERS 52

8.3 NOVEL THERAPEUTICS 52

9 U.S. MENIERE’S DISEASE DRUG MARKET, BY DRUG TYPE 53

9.1 OVERVIEW 54

9.2 GENERICS 57

9.3 BRANDED 57

10 U.S. MENIERE’S DISEASE DRUG MARKET, BY ROUTE OF ADMINISTRATION 58

10.1 OVERVIEW 59

10.2 ORAL 62

10.3 PARENTERAL 62

11 U.S. MENIERE’S DISEASE DRUG MARKET, BY END USER 63

11.1 OVERVIEW 64

11.2 HOMECARE 67

11.3 HOSPITALS 67

11.4 SPECIALTY CLINICS 67

11.5 ACADEMIC AND RESEARCH INSTITUTE 67

12 U.S. MENIERE’S DISEASE DRUG MARKET, BY DISTRIBUTION CHANNEL 68

12.1 OVERVIEW 69

12.2 RETAIL PHARMACIES 71

12.3 HOSPITAL PHARMACIES 72

12.4 ONLINE PHARMACIES 72

13 U.S. MENIERE’S DISEASE DRUG MARKET, COMPANY LANDSCAPE 73

14 COMPANY PROFILE 74

14.1 PFIZER INC. 74

14.1.1 COMPANY SNAPSHOT 74

14.1.2 REVENUE ANALYSIS 74

14.1.3 PRODUCT PORTFOLIO 75

14.1.4 RECENT DEVELOPMENT 75

14.2 MYLAN N.V. 76

14.2.1 COMPANY SNAPSHOT 76

14.2.2 REVENUE ANALYSIS 76

14.2.3 PRODUCT PORTFOLIO 77

14.2.4 RECENT DEVELOPMENT 77

14.3 BAUSCH HEALTH 78

14.3.1 COMPANY SNAPSHOT 78

14.3.2 REVENUE ANALYSIS 78

14.3.3 PRODUCT PORTFOLIO 79

14.3.4 RECENT DEVELOPMENT 79

14.4 AKORN, INCORPORATED 80

14.4.1 COMPANY SNAPSHOT 80

14.4.2 REVENUE ANALYSIS 80

14.4.3 PRODUCT PORTFOLIO 81

14.4.4 RECENT DEVELOPMENT 81

14.5 AMNEAL PHARMACEUTICALS LLC 82

14.5.1 COMPANY SNAPSHOT 82

14.5.2 REVENUE ANALYSIS 82

14.5.3 PRODUCT PORTFOLIO 83

14.5.4 RECENT DEVELOPMENT 83

14.6 BAXTER 84

14.6.1 COMPANY SNAPSHOT 84

14.6.2 REVENUE ANALYSIS 84

14.6.3 PRODUCT PORTFOLIO 85

14.6.4 RECENT DEVELOPMENT 85

14.7 F. HOFFMANN-LA ROCHE LTD 86

14.7.1 COMPANY SNAPSHOT 86

14.7.2 REVENUE ANALYSIS 86

14.7.3 PRODUCT PORTFOLIO 87

14.7.4 RECENT DEVELOPMENT 87

14.8 FRESENIUS KABI AG 88

14.8.1 COMPANY SNAPSHOT 88

14.8.2 REVENUE ANALYSIS 88

14.8.3 PRODUCT PORTFOLIO 89

14.8.4 RECENT DEVELOPMENT 89

14.9 HIKMA PHARMACEUTICALS PLC 90

14.9.1 COMPANY SNAPSHOT 90

14.9.2 REVENUE ANALYSIS 90

14.9.3 PRODUCT PORTFOLIO 91

14.9.4 RECENT DEVELOPMENT 91

15 PIPELINE COMPANY PROFILE 92

15.1 AURIS MEDICAL 92

15.1.1 COMPANY SNAPSHOT 92

15.1.2 REVENUE ANALYSIS 92

15.1.3 PIPELINE PORTFOLIO 93

15.2 ORBIS BIOSCIENCES, INC. 94

15.2.1 COMPANY SNAPSHOT 94

15.2.2 PIPELINE PORTFOLIO 94

15.3 OTOLOGIC PHARMACEUTICS 95

15.3.1 COMPANY SNAPSHOT 95

15.3.2 PIPELINE PORTFOLIO 95

15.4 OTONOMY, INC. 96

15.4.1 COMPANY SNAPSHOT 96

15.4.2 REVENUE ANALYSIS 96

15.4.3 PIPELINE PORTFOLIO 97

15.5 QUARK 98

15.5.1 COMPANY SNAPSHOT 98

15.5.2 PIPELINE PORTFOLIO 98

15.6 SOUND PHARMACEUTICALS 99

15.6.1 COMPANY SNAPSHOT 99

15.6.2 PIPELINE PORTFOLIO 99

16 QUESTIONNAIRE 100

17 RELATED REPORTS 103

UU

TABLE 1 U.S. MENIERE’S DISEASE DRUG MARKET, BY TYPE, 2018-2027 (USD MILLION) 41

TABLE 2 U.S. MENIERE’S DISEASE DRUG MARKET, BY TREATMENT, 2018-2027 (USD MILLION) 46

TABLE 3 U.S. OFF LABEL DRUGS IN MENIERE’S DISEASE DRUG MARKET, BY TREATMENT, 2018-2027 (USD MILLION) 47

TABLE 4 U.S. TRANQUILLIZERS IN MENIERE’S DISEASE DRUG MARKET, BY TREATMENT, 2018-2027 (USD MILLION) 48

TABLE 5 U.S. ANTIHISTAMINIC AGENTS IN MENIERE’S DISEASE DRUG MARKET, BY TREATMENT, 2018-2027 (USD MILLION) 49

TABLE 6 U.S. DIURETIC AGENTS IN MENIERE’S DISEASE DRUG MARKET, BY TREATMENT, 2018-2027 (USD MILLION) 50

TABLE 7 U.S. ANTIBIOTIC AGENTS IN MENIERE’S DISEASE DRUG MARKET, BY TREATMENT, 2018-2027 (USD MILLION) 51

TABLE 8 U.S. CORTICOSTEROIDS IN MENIERE’S DISEASE DRUG MARKET, BY TREATMENT, 2018-2027 (USD MILLION) 51

TABLE 9 U.S. MENIERE’S DISEASE DRUG MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION) 56

TABLE 10 U.S. MENIERE’S DISEASE DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION) 61

TABLE 11 U.S. MENIERE’S DISEASE DRUG MARKET, BY END USER, 2018-2027 (USD MILLION) 66

TABLE 12 U.S. MENIERE’S DISEASE DRUG MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION) 71